Sermorelin (GHRH 1-29)
The first 29 amino acids of endogenous GHRH
At a glance
What it is: The first 29 amino acids of endogenous GHRH.
Primary research applications:
- Pediatric growth hormone deficiency (historically approved)
- Off-label anti-aging and body composition
Editorial summary: Sermorelin is the minimal active region of natural GHRH and has real FDA-approved history in pediatric GH deficiency. The anti-aging and wellness use in adults is off-label and much less rigorously supported.
What is Sermorelin?
Sermorelin acetate is the synthetic 1–29 fragment of human GHRH — the shortest sequence that retains full GHRH activity. It was FDA-approved as Geref for pediatric GH deficiency from the 1990s to mid-2000s, when the manufacturer discontinued commercial production.[1]
Mechanism of action
Identical in mechanism to native GHRH — binds the pituitary GHRH receptor, stimulating endogenous GH release. Half-life is short (~10–15 minutes) so dosing is typically once daily at bedtime to coincide with natural nocturnal GH pulses.
What the research shows
The peer-reviewed literature on Sermorelin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Raises GH and IGF-1 | Supported in clinical use | Supported |
| Treats pediatric GH deficiency | FDA-approved historically | Supported |
| Reverses age-related GH decline in adults | Biologically plausible; mixed small studies | Plausible |
| Produces clinically meaningful anti-aging effects | No rigorous adult RCT evidence | Preliminary |
Reported user experiences
How the research describes administration
Subcutaneous injection, typically at bedtime. This describes the historical clinical use.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Sermorelin has the most legitimate regulatory history of any GH-releasing peptide on this site. For adult anti-aging use, it's a milder, more physiologic option than CJC-1295 but with the same caveat: real pharmacology, weak outcome evidence.
Frequently asked questions
Is sermorelin FDA-approved?
It was approved as Geref for pediatric GH deficiency but commercial production was discontinued in 2008 by the original manufacturer. It remains available through compounding pharmacies.
How does sermorelin compare to CJC-1295?
Same target (GHRH receptor), but sermorelin has a much shorter half-life. CJC-1295 'with DAC' is long-acting; CJC-1295 'without DAC' (Mod GRF 1-29) is essentially sermorelin with a few stability modifications.
References
- FDA Orange Book record for sermorelin acetate (Geref). Also Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. https://pubmed.ncbi.nlm.nih.gov/18046909/
- Thorner MO, et al. Acceleration of growth rate in growth hormone-deficient children treated daily with growth hormone releasing hormone (1-29)NH2. Pediatr Res. 1988;24(2):145-51. https://pubmed.ncbi.nlm.nih.gov/3137532/